

The 14th Annual Meeting of Chinese American Pathologists Association



Saturday, March 12, 2:30 – 4:30 PM, 2016
Sheraton Hotel Metro Ballroom A, Seattle, WA

The Mission of the CAPA



The primary mission of the CAPA is to improve educational opportunities and professional skills of practicing pathologists of Chinese ethnicity, by promoting communication, friendship and cultural exchange, and by advancing the science and practice of pathology and laboratory medicine.

<http://www.capaht.org>

CAPA Acknowledges the Following Sponsors for Their Support

Advanced Cell Diagnostics, Inc.

American Society of Clinical Pathology

BioGenex

Cell Marque

Dian Diagnostics

Foundation Medicine

Geisinger IHC Reference Lab

Gopath

Kingmed

Maixin

Motic


NovoDiax, Inc.

Roche/Ventana

Roche Diagnostics China

Rosetta Genomics

The CAPA Annual Report 2015-2016



Dear CAPA friends:

It was my great honor to serve as the Chinese American Pathologists Association (CAPA) President in 2015. It certainly was a great year for CAPA! Together, we have accomplished the goals that I announced at the last CAPA Annual Business Meeting in Boston. Congratulations and thanks to all CAPA members, especially those of you who have been actively involved in and contributed to this great pathology community! Because of your strong support, dedication and contributions, CAPA achieved

many goals and reached many impressive new milestones in 2015, such as:

- Establishing functional CAPA Subcommittees;
- Hosting the first CAPA Diagnostic Pathology Course in New York City;
- Co-organizing the first CAPA-Beijing Diagnostic Pathology Course in Beijing;
- Participating in the Chinese Society of Pathology (CSP) 2015 Annual Meeting in Kunming;
- Participating in the 9th AP-IAP Meeting in Brisbane, Australia;
- Publishing quarterly CAPA eNewsletters;
- Refining the CAPA website and increasing the number of website visits;
- Authoring a special section of review articles based on the CAPA Diagnostic Pathology Course for the *Archives of Pathology and Laboratory Medicine*;
- Preparing for the first CAPA Companion Meeting at the 2016 CAP meeting;
- Recruiting many more members, including many lifetime members;
- Attracting more sponsors to make CAPA more financially stable and healthier than ever;
- Improving management of the CAPA pre-existing accounts and completing an auditing process;
- Creating two new CAPA awards - CAPA Honorary Award and CAPA Member of the Year Award.


For the complete annual report, please go to the CAPA website (<http://www.capaht.org/>) or read the 4th issue of the CAPA eNewsletter.

In summary, the CAPA community is well-prepared and positioned for future growth. Again, I am honored to have had the opportunity to serve as its President in 2015! My professional life has been greatly enriched, inspired, and influenced by the many friends and colleagues I have met along the way, especially those with whom I have had close interactions during the last year. I am grateful to the CAPA Executive Committee, Subcommittee chairs and co-chairs, Subcommittee members, and all the members and volunteers who worked closely with me to accomplish these ambitious goals. Together, we did it! Once again, I sincerely appreciate all sponsors for their very generous support. Finally, I strongly encourage all of you to be volunteers and more actively involved in all CAPA activities, now and in the future, because this is OUR OWN pathology community! Now, Dr. Huamin Wang and the entire CAPA leadership team will take the CAPA to the next level. Together, we will build an even stronger CAPA!

Respectfully submitted,

Fan Lin, MD, PhD
CAPA President, 2015-2016

Welcome to the 14th Chinese American Pathologists Association (CAPA) Annual Meeting In Seattle!



Congratulations to the presidents-elect, Dr. Ping Tang!

It is my distinguished honor and privilege to be elected as the president of the Chinese American Pathologists Association (CAPA) for 2016-2017.

CAPA has become an internationally recognized organization within the pathology community, thanks to the strong leadership and strategic visions of our past presidents; dedication from our current and past executive committee members, subcommittee chairs, co-chairs and members; and strong support from our active members.

I would like to express my special thanks to Dr. Fan Lin for his strong leadership and to his leadership team and many active members for their hard work and outstanding contributions in the past year. We are having another historic and successful gathering in Seattle, because our members contributed their precious time and effort with the leadership of Dr. Fan Lin and his team. I would like to thank our sponsors for their generous support and professional partnerships with CAPA. I would like to thank and welcome all CAPA members as well as our distinguished friends in pathology from China to this meeting.

Strong and dedicated teamwork is the major force that has driven the CAPA forward at an unprecedented pace in recent years. Under the outstanding leadership of Dr. Fan Lin, we have achieved numerous milestones in CAPA's history in the past year as listed in Dr. Lin's CAPA Annual Report. As we move into the next year, I look forward to working with our leadership teams and active members to continue these great programs and to implement new programs, including the 1st CAPA Companion Meeting at 2016 CAP Annual Meeting, the CAPA Diagnostic Pathology Course in Houston, the CAPA-Beijing Pathology Symposium etc. We are also in the process of amending the CAPA bylaws; improving the CAPA web site; validating and organizing our membership databases; and updating CAPA member email list to better communication with our members.

Together as a team, we will make CAPA a stronger and better organization in the coming years!

Sincerely yours,

Huamin Wang, MD, PhD
Professor

Department of Pathology & Department of Translation Molecular Pathology
University of Texas M.D. Anderson Cancer Center, Houston, TX
CAPA President, 2016-2017

The 14th CAPA Annual Business Meeting Agenda
Sheraton Hotel Metro Ballroom A, 2:30 – 4:30 PM
Saturday, March 12, 2016, Seattle, WA

1:30 – 2:30 PM | Registration and Refreshments

2:30 – 3:00 PM | CAPA Business Meeting

- Opening remarks and CAPA Annual Report: Dr. Fan Lin, CAPA President, 2015-2016
- CAPA Finance Report: Dr. Zongming (Eric) Chen, CAPA Treasurer
- CAPA Membership Update: Dr. Lizhen Gui, Chair of Membership Subcommittee
- CAPA Bylaws Changes: Dr. Huamin Wang, CAPA President, 2016-2017

3:00 – 3:15 PM | Scientific Presentations by Meeting Platinum Sponsors

- Advanced Cell Diagnostics, Inc.
- Foundation Medicine
- NovoDix

3:15 – 4:00 PM | Presenting CAPA Awards

- CAPA Honorary Award: Presented by Dr. Fan Lin, CAPA President, 2015-2016
- CAPA/ACD Distinguished Pathologist Awards: Presented by Drs. Yuling Lou (ACD CEO) and Fan Lin
- CAPA/Zu-Hua Gao Service Award: Presented by Dr. Zu-Hua Gao, CAPA President 2012-2013
- CAPA Member of the Year Award: Presented by Dr. Fan Lin, CAPA President 2015-2016
- CAPA/Gopath Best Abstract Awards: Presented by Drs. Hanlin Wang and Zhenbin Lu
- CAPA/Motic Best Abstract Awards: Presented by Dr. Guoping Cai and Mr. Richard Yeung, Motic CEO
- CAPA Past Presidents Recognition Plaques: Presented by Dr. Chin-Lee Wu

4:00 – 4:15 PM | Remarks from CAP, USCAP and CSP Officials

- Dr. Richard Friedberg, CAP President
- Dr. David Kaminsky, USCAP EVP
- Dr. Xiu-Wu Bian, CSP President

4:15 – 4:30 PM | Looking Forward

- Dr. Huamin Wang, CAPA President 2016-2017

4:30 – 5:30 PM | Bus, Taxi, or Walking to China Harbor Restaurant

Free Buses (Shuttle Express) available at 5:00 PM at the front door of Sheraton Hotel.

China Harbor Restaurant [<http://www.seattlechinaharbor.com>]; 2040 Westlake Avenue N., Seattle, WA 98109; (206) 286-1688]

5:30 – 10:00 PM | CAPA Annual Dinner Party and Karaoke

CAPA Awards


CAPA Honorary Award



Philip T. Cagle, MD, is the editor-in-chief of the Archives of Pathology & Laboratory Medicine, Director of Pulmonary Pathology at Houston Methodist Hospital and Professor of Pathology and Laboratory Medicine at Weill Cornell Medical College. Dr. Cagle received his MD degree from the University of Tennessee College of Medicine in Memphis in 1981. After completing his pathology residency at the Baylor College of Medicine in Houston, Texas, from 1981 to 1985, he completed a fellowship in pulmonary pathology at the University of British Columbia in Vancouver, Canada, from 1985 to 1987. In 1987, he joined the faculty at Baylor College of Medicine and joined the faculty at Houston Methodist Hospital and Weill Cornell Medical College in 2004. Dr. Cagle is Co-Chair and co-author of the CAP/IASLC/AMP Lung Cancer Predictive Biomarker Guidelines, Chair of the CAP Cancer Biomarker Reporting Committee and Advisor to several other CAP Committees. He is current Program Committee Chair and former President of the Pulmonary Pathology Society as well as Education Council Chair for the Texas Society of Pathologists. He is editor of 16 textbooks on pulmonary pathology, editor of 2 electronic books, series editor for 3 book series and author of 100 book chapters and 200 journal articles. Dr. Cagle is a recipient of the CAP Distinguished Patient Care Award, the CAP Pathologist of the Year Award (2013), the Alfred Soffer Research Award from the American College of Chest Physicians and the Texas Society of Pathologists John J. Andujar, MD Citation of Merit Award.

CAPA/ACD Distinguished Pathologist Award

Hanlin L. Wang, MD, PhD, is a Professor of Pathology, Chief of Gastrointestinal Pathology and Director of Gastrointestinal/Liver Pathology Fellowship Program at David Geffen School of Medicine, University of California at Los Angeles. Dr. Wang graduated from Hubei Medical College (now Wuhan University School of Medicine) and obtained his PhD degree in Biomedical Sciences from Mayo Clinic. He completed pathology residency training at University of Chicago followed by gastrointestinal/liver pathology fellowship training at the same institution with Dr. John Hart. Dr. Wang's research interests have been medical and neoplastic gastrointestinal and hepatobiliary diseases, with a focus on biomarkers that may have diagnostic, therapeutic or prognostic significance. His publications include more than 130 research articles, 34 book chapters, and two books (co-editors). Dr. Wang is one of the earliest members of CAPA.



Jinsong Liu, MD, PhD, is a professor with tenure in the Department of Pathology at The University of Texas M. D. Anderson Cancer Center. He received his Ph.D. degree in Biochemistry from Case Western Reserve University in 1991 and completed his pathology residency and surgical pathology fellowship training at New York University School of Medicine from 1994 to 1999. He is certified by American Board of Anatomic Pathology. He joined the faculty in the Department of Pathology at The University of Texas M. D. Anderson Cancer in 1999 as an Assistant Professor and was promoted to Associate Professor in 2004 and professor in 2009 with tenure. Dr. Liu is internationally recognized for his expertise in diagnosis of gynecologic malignancy and research achievements in ovarian cancer. His research has focused on inflammation, tumor microenvironment, cancer stem cells, and prognostic markers for ovarian cancer. Dr. Liu's research has been continuously funded by more than 30 grants from different funding agencies in the past 15 years. Dr. Liu has been an editorial member of several reputable journals. Dr. Liu has co-authored 200 peer reviewed original publications and 22 reviews. Dr. Liu has been a member of CAPA since her establishment in 2003 and former president of CAPA (2013-2014).

CAPA Awards (Continued)

CAPA/Zu-Hua Gao Service Award

Marilyn M. Bui, MD, PhD, is Senior Member of the Anatomic Pathology Department, the Scientific Director of Analytic Microscopy Core, and the Program Leader of Anatomic Pathology Education at Moffitt Cancer Center. She is also a Professor and Director of Cytopathology Fellowship at the University of South Florida Morsani College of Medicine. She has expertise in sarcoma pathology, cytopathology, and digital pathology. In CAPA, she served as a member of the Executive Committee and chaired the Education Committee for the past two years. Recently Dr. Bui is recognized by *The Pathologist* magazine as one of its inaugural Top 100 Power List, which celebrates the exceptional achievements of those who have really had an impact on the field of pathology; and to highlight the truly groundbreaking work of laboratory medicine and its intrinsic role in patient care and the molecular revolution.



CAPA Member of the Year Award



Zongming (Eric) Chen
MD, PhD

**CAPA Treasurer for
2015-2018**



Ruoqing Huang
MD, PhD

**A Strong CAPA Sup-
porter and Advocate**



Fan Chen
MD, PhD

**Co-chair for CAPA
Membership and Publi-
cation Subcommittees
2015-2017**




Huihong Xu
MD, PhD

**Key Member of CAPA
Finance Subcommittee
2015-2017**



Lizhen Gui
MD, PhD

**Chair for CAPA Mem-
bership Subcommittee
2015-2017**



Lanjing Zhang
MD, MS

**Co-chair for CAPA
Education Subcommit-
tee 2015-2017**

CAPA Awards (Continued)

CAPA/Gopath Best Abstract Award

First Prize: **Wei Wang, MD, PhD, UT MD Anderson Cancer Center.** Risk stratification of additional chromosomal changes in chronic myelogenous leukemia in era of tyrosine kinase inhibitor therapy

Second Prize: **Hongyan Dai, MD, PhD, University of Kansas.** miR-139 in breast cancer tumors and serum a surrogate marker for tumor aggression

Second Prize: **Qingqing Liu, MD, PhD, University of Massachusetts.** Hemizygous deletion of RB1 gene in chromophobe renal cell carcinoma and its potential role in distinguishing chromophobe renal cell carcinoma from renal oncocytoma

Third Prize: **Jinhua Piao, MD, St. Louis University.** Vasodilator stimulated phosphoprotein (VASP) immunoreactivity is associated with lymphovascular invasion of colorectal adenocarcinoma (CRC) leading to liver and lymph node metastases

Third Prize: **Wendi Zhou, MD, PhD, University of California at Los Angeles.** Diagnostic utility of clusterin immunostaining in differentiating hepatocellular carcinoma from tumors of other origins

Third Prize: **Bing Ren, MD, PhD, University of Pittsburgh.** Programmed death ligand-1 (PD-L1) expression in mismatch repair deficient gastric tumors and gastric tumors positive for Epstein-Barr virus

CAPA/Motic Best Abstract Award

First Place Prize

A new variant of phosphaturic mesenchymal tumor exclusively involving alveolar bone: a clinicopathological analysis of 17 cases

Huanwen Wu¹, Marilyn M. Bui², Yunxia Meng¹, Lian Zhou³, Xinxin Mao¹, Zhiyong Liang¹, Dingrong Zhong¹

¹ Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China

² Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, FL, USA

³ Department of Stomatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China

Second Place Prize

Zic2 promotes tumor growth and metastasis via PAK4 in hepatocellular carcinoma

Shi-Xun Lu^{1,2}, Chris Zhiyi Zhang^{1,2}, Rong-Zhen Luo^{1,2}, Li-Li Liu^{1,2}, Jia Fu^{1,2}, Jing-Ping Yun^{1,2}.

¹ Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China

² Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China

CAPA Awards (Continued)

CAPA/Motic Best Abstract Award (Continued)

Second Place Prize (Continued)

MicroRNA expression of Peripheral T and NK cell lymphomas in one hospital

Lin Feng¹, Linshu Zeng², Ling Shan², Yanning Gao¹, Yu Liu¹, Ning Lu², Shujun Cheng¹, Xiaoli Feng²

¹ State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, Cancer Hospital and Institute, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China

² Department of Pathology, Cancer Hospital and Institute, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China

Third Place Prize

Parameters associated with recurrence of pT1N0 esophageal squamous cell carcinoma after radical esophagectomy

Liyan Xue^{1,8}, Xiumin Qin², Yong Liu², Jun Liang³, Feiyue Feng⁴, Hua Lin⁵, Zhouguang Hui³, Yueming Zhang², Xuemin Xue¹, Liqun Ren^{1,6}, Shuangmei Zou¹, Xiuyun Liu¹, Yanling Yuan¹, Jianming Ying¹, Luhua Wang³, Sanford M. Dawsey⁷, Guiqi Wang², Ning Lu¹

¹ Department of Pathology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

² Department of Endoscopy, Cancer Institute & Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

³ Department of Radiation Oncology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

⁴ Department of Thoracic Surgery, Cancer Institute & Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

⁵ Department of Medical Record, Cancer Institute & Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

⁶ Department of Pathology, Chengde Medical College, Chengde, China

⁷ Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA

High Risk HPV Testing and Report Rate: Result from the Largest CAP Certified Independent Laboratory in China

Baowen Zheng¹, Zaibo Li², Zhenyu Zeng¹, Congde Chen¹, Ja You¹, Lingyun Tan¹, Chengquan Zhao³

¹ Guangzhou Kingmed Diagnostics, Guangzhou, Guangdong

² Department of Pathology, Ohio State University Medical Center, Columbus, Ohio

³ Department of Pathology, Magee-Women's Hospital of UPMC, Pittsburgh, PA

Endocervical curettage should be performed in women older than 35 with cytological high-grade squamous intraepithelial lesions or carcinomas regardless of colposcopy impression

Yan Song¹, Yu-Qian Zhao², Ling Li¹, Qin-Jin Pan¹, Wen-Hua Zhang³, Fang-Hui Zhao², Wen Chen², Xun Zhang¹, You-Lin Qiao²

¹ Department of Pathology

² Department of Epidemiology

³ Department of Gynecology

Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

CAPA Past Presidents Recognition

Chin-Lee Wu (2002-2005)

Ximing Yang (2006)

Bin Yang (2007)

Shu-Yuan Xiao (2008)

Shuan Li (2009)

Ming Zhou (2010)

Steven Shen (2011)

Zu-Hua Gao (2012)

Jinsong Liu (2013)

Qihui (Jim) Zhai (2014)

Fan Lin (2015)

CAPA Executive Committee

Fan Lin (President 2015-2016)

Huamin Wang (President 2016-2017)

Ping Tang (President-elect 2017-2018)

Qihui (Jim) Zhai (Past President 2014-2015)

Zongming (Eric) Chen (Treasurer)

Marilyn Bui

Guoping Cai

Lizhen Gui

Chen Liu

Huan-You Wang

Lanjing Zhang

Jun Zhang

CAPA Publication Subcommittee/Editing Team

Huan-You Wang

Jun Zhang

Fan Chen

Jie Song

Zenggang Pan

Kar-Ming Fung

Longwen Chen

Yajue Huang

Huimiao Jiang

Jie Song

Design for Brochure

Fan Chen (2016)

Huihui Ye (2015)

Zenggang Pan (2015)

Website Master

Jie Song

Design for eNewsletter

Fan Chen

CAPA Lifetime Members

Bu, Lihong	Li, Hong Catherine	Shen, Steven	Yang, Hongyu
Cai, Jianping	Li, Shuan	Shen, Youjun	Yang, Ximing
Chen, Baorong	Liang, Mei	Sun, Wei	Ye, Huihui
Chen, Fan	Liang, Songlin	Tan, Dongfeng	Yin, Hong (Julie)
Chen, Fayu (Mark)	Lin, Fan	Tang, Daniel	Yu, Hongbo
Chen, Helen	Lin, Jingmei	Tang, Ping	Yu, Limin
Chen, Longwen	Liu, Haiyan	Tang, Wozhan	Zhai, Qihui (Jim)
Chen, Qianghua	Liu, James	Wang, Beverly	Zhang, David
Cheng, Liang	Liu, Jinsong	Wang, Hanlin	Zhang, Jun
Cheng, Lirong	Liu, Wendy	Wang, Liang (Larry)	Zhang, Lanjing
Fan, Rong	Liu, Wenhua	Wu, Chin-Lee	Zhang, Xiaohong
Gui, Lizhen	Luo, Frank	Xiao, Shu-Yuan	Zhao, Chengquan
Hu, Huankai	Luo, Pifu	Xie, Silvia Xiuyan	Zhao, Xiaohui
Huang, Jiaoti	Ma, Xiaoling	Xin, Wei	Zhao, Song Qing
Huang, Ruoqing	Pei, Zhiheng	Xu, Huihong	Zheng, Wenxin
Jiang, Ming	Pu, Robert	Xu, Xiaomeng	Zhou, Chen
Jiang, Yuying	Qian, Xiaohua	Yang, Bin	Zhou, Zhongren
Lee, Peng			Zu, Youli

CAPA Senior Advisory Council (SAC) (Alphabetical order)

Longwen Chen, MD, PhD Mayo Clinic Arizona	Wendy Liu, MD, PhD University Hospitals Case Medical Center	Ximing J. Yang, MD, PhD Northwestern University
Fang Fan, MD, PhD University of Kansas Medical Center	Danielle Lu, MD Huntington Memorial Hospital, Pasadena, CA	Qihui (Jim) Zhai, MD Mayo Clinic
Zu-hua Gao, MD, PhD, FRCPC McGill University Health Center	Steven Shen, MD, PhD Houston Methodist Hospital Weill Medical College of Cornell University	Lanjing Zhang, MD, MS University Medical Center of Princeton at Plainsboro; Rutgers University
Yun Gong, MD UT MD Anderson Cancer Center	Ping Tang, MD, PhD University of Rochester Medical Center	Jun Zhang, MD Mayo Clinic
Jiaoti Huang, MD, PhD UCLA	Beverly Wang, MD UC Irvine Medical Center	Paul J. Zhang, MD Hospital of the University of Pennsylvania, Perelman School of Medicine
Qin Huang, MD, PhD Harvard Medical School, VA Boston Healthcare System	Hanlin Wang, MD, PhD UCLA	Chengquan Zhao, MD Magee-Womens Hospital University of Pittsburgh
Pei Hui, MD, PhD Yale University School of Medicine	Jun Wang, M.D. Loma Linda University Medical Center	Wenxin Zheng, MD University of Arizona College of Medicine
Maomi Li, MD, PhD Integrated Oncology (LabCorp Specialty Testing Group)	Chin-Lee Wu, MD, PhD Massachusetts General Hospi- tal; Harvard Medical School	Chen Zhou, MD, PhD University of British Columbia, Vancouver, Canada
Shuan C. Li, MD Orlando Health	Shu-Yuan Xiao, M.D. University of Chicago	Ming Zhou, MD, PhD New York University Medical Center, Tisch Hospital
Fan Lin, MD, PhD Geisinger Medical Center	Wei Xin, MD, PhD University Hospital Case Medical center	Youli Zu, MD, PhD Houston Methodist Hospital, Weill Medical College of Cornell University
Jinsong Liu, MD, PhD UT MD Anderson Cancer Center	Haodong Xu, MD, PhD UCLA	
	Bin Yang, MD, PhD Cleveland Clinic	

Stains are a good thing ...
Quality stains are our thing

Geisinger

Please stop by and see
 Geisinger IHC at the USCAP
 2016 Annual Meeting in Seattle
 from March 14 – 16 at booth #538.


geisingerihc.com



10 MINUTE INTRAOPERATIVE DIRECT IHC

Available Products:

- ihcDirect AE1/AE3
- ihcDirect Mart-1
- ihcDirect CK8/18
- ihcDirect Synaptophysin
- ihcDirect Herceptin



Time In Minute	Procedure
0.5	Fixation
0.1	Wash in PBS
0	No Blocking
5	PolyHRP-Antibody
0.1	Wash in Water
1	DAB
0.1	Wash in Water
2-3	Counter Staining + Dehydration + Coverslipping

9-10 Total Time



VISIT www.novodiox.com
 CALL 1.888.439.2716
 EMAIL novoinfo@novodiox.com



Digital Scanner and Telepathology Platform
Automated Cervical Cancer Screening
Cancer DNA Ploidy Analysis
Cytology and Surgical Pathology Services

麦克奥迪(厦门)医疗诊断系统有限公司
MOTIC XIAMEN MEDICAL DIAGNOSTIC SYSTEMS CO. LTD

厦门麦克奥迪医学检验所
XIAMEN MOTIC MEDICAL LABORATORY




Motic Medical Diagnostic
Systems, Xiamen, China
med.motic.com



MXB[®]
Biotechnologies

Maixin provides comprehensive range of solutions for immunohistochemistry



Biotechnologies

福州迈新生物技术开发有限公司

☎: 400-8899-863/800-8881-156




Game Changer




Integrated
eFISHiency
System

- FISH Probes
 - Detection Systems
 - Smart Automation
- Hands-On Time < 30 min.
Up to 10 protocols per run



Xmatrix[®]NANO

miRNA *In Situ* - Dawn of a New Era



For Clinical Research & Tumour Analysis:

- Cancer of Unknown Primary
- Undifferentiated Tumors
- Cancer Staging



Xmatrix[®]ELITE INFINITY and NANO
miRNA-ISH Automation

Rare for you but not for Foundation Medicine

RARE/UNCOMMON SUBTYPE	PERTINENT TUMOR DRIVER	FOA APPROVED TARGETED THERAPIES	FOA APPROVED THERAPIES IN ANOTHER TUMOR TYPE
Non-Serous Ovarian Cancers, eg: Ovarian Clear cell	BRCA1/2	Olaparib	Trastuzumab, Pertuzumab Pazopanib, Ponatinib Temsirolimus, Everolimus Olaparib and others
	ERBB2		
	FGFR1/2/3		
	AKT1/2		
	PALB2		
Pancreatobiliary Cancers: ■ Cholangiocarcinoma ■ Pancreas ■ Gallbladder	IDH1/2	Palbocicib	Azacitidine, Decitabine Trastuzumab, Pertuzumab, Atizumab Pazopanib Dabrafenib, Trametinib, Vemurafenib Everolimus Trastuzumab, Pertuzumab Trastuzumab, Pertuzumab Trametinib Trastuzumab, Pertuzumab
	ERBB2		
	FGFR2		
	BRAF		
	PTEN		
	BRCA2		
	ERBB2		
	BRAF		
	ERBB2		
Uncommon subtypes of breast cancer	CCND1	Palbocicib	Olaparib Afinib, Celecoxib Erlotinib, Lapatinib, Pertuzumab, Trastuzumab Everolimus, Temsirolimus
	BRCA1/2		
	ESFR		
	ERBB2		
	PIK3R1, NF1, STK11, AKT2/3, PTEN		
Salivary Gland	ERBB2		Trastuzumab, Pertuzumab Cetuximab, Lapatinib Temsirolimus, Everolimus Olaparib Trametinib, Dabrafenib
	ESFR		
	PTEN		
	BRCA1/2		
	BRAF		

Comprehensive genomic profiling using FoundationOne has been performed on > 16,000 uncommon tumor cases. Learn more at: [USCAP Annual Meeting Booth #541](#)



No antibody. No problem.

Breakthrough multiplex RNA
in situ hybridization for any gene
with RNAscope® technology.

Because up to 76% of protein-coding genes have no reliable antibody for immunohistochemistry (IHC), your research often comes to a screeching halt while you wait for a new antibody to be developed. With rapid probe design and universal assay workflows for any gene, RNAscope® technology frees you from the hassles of antibody screening, saving you precious time and effort, while driving publication quality data.

Learn more about RNAscope® Technology
at www.aodbio.com



PD-L1 detection in lung cancer sample using
RNAscope® 2.5 HD Reagent Kit-RED